Literature DB >> 8494198

Current issues in the use of theophylline.

H Milgrom1, B Bender.   

Abstract

Theophylline is a safe and effective medication for the management of chronic asthma. It reduces nocturnal bronchospasm and airways hyperresponsiveness, and its addition to effective doses of beta-agonists and corticosteroids leads to further improvement in symptom control. These properties are the result of actions other than simple bronchodilation, and there is a strong possibility that anti-inflammatory activity accounts for its clinical advantages. Serious side effects are uncommon and their rate can be further reduced through appropriate precautions. Recent studies have alleviated the concern over cognitive and behavioral side effects in children.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8494198     DOI: 10.1164/ajrccm/147.6_Pt_2.S33

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  5 in total

Review 1.  The outpatient diagnosis and management of chronic obstructive pulmonary disease: pharmacotherapy, administration of supplemental oxygen, and smoking cessation techniques.

Authors:  R M Schapira; L F Reinke
Journal:  J Gen Intern Med       Date:  1995-01       Impact factor: 5.128

2.  Concurrent oral and inhalation drug delivery using a dual formulation system: the use of oral theophylline carrier with combined inhalable budesonide and terbutaline.

Authors:  Rania O Salama; Paul M Young; Daniela Traini
Journal:  Drug Deliv Transl Res       Date:  2014-06       Impact factor: 4.617

Review 3.  Nocturnal asthma uncontrolled by inhaled corticosteroids: theophylline or long-acting beta2 agonists?

Authors:  T D Holimon; C C Chafin; T H Self
Journal:  Drugs       Date:  2001       Impact factor: 9.546

4.  Administration of phosphodiesterase inhibitors and an adenosine A1 receptor antagonist induces phrenic nerve recovery in high cervical spinal cord injured rats.

Authors:  S Kajana; H G Goshgarian
Journal:  Exp Neurol       Date:  2008-01-05       Impact factor: 5.330

5.  Differential effects of non-selective and selective phosphodiesterase inhibitors on human eosinophil functions.

Authors:  A Hatzelmann; H Tenor; C Schudt
Journal:  Br J Pharmacol       Date:  1995-02       Impact factor: 8.739

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.